HK Stock Market Move | Hangzhou Tigermed Consulting (03347) rose more than 7%, with net profit attributable to the parent increasing by 98.73% year-on-year in the third quarter.
Tiger Pharmaceuticals (03347) surged more than 7%, as of the time of writing, it was up 7.7% to HK$46.44, with a trading volume of HK$21.36 million.
Hangzhou Tigermed Consulting (03347) rose more than 7%, as of press time, it rose by 7.7%, to 46.44 Hong Kong dollars, with a turnover of 213.607 million Hong Kong dollars.
In terms of news, Hangzhou Tigermed Consulting released its third quarter report for 2025, with the group earning operating income of 5.26 billion yuan in the first three quarters, a decrease of 0.82% year-on-year; net profit attributable to the parent company was 1.02 billion yuan, an increase of 25.45% year-on-year. Looking at the third quarter alone, the company achieved operating income of 1.75 billion yuan, an increase of 3.86% year-on-year; net profit attributable to the parent company was 637 million yuan, an increase of 98.73% year-on-year.
Related Articles

"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"

Guosen: RWA welcomes the era of strict supervision.

Wondershare Technology Group (300624.SZ) has upgraded its Wondershare Filmora desktop version: free video editing, better AI results!
"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"

Guosen: RWA welcomes the era of strict supervision.

Wondershare Technology Group (300624.SZ) has upgraded its Wondershare Filmora desktop version: free video editing, better AI results!

RECOMMEND

Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026

Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026

Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026


